Skip to content
  • BTC $58,830 −6.8%
  • ETH $1,629 −8.8%
  • SOL $69.06 −7.4%
  • BNB $541.52 −8.1%
  • XRP $0.9075 −7.3%
  • DOGE $0.0541 −8.5%
  • ADA $0.1409 −8.6%

GRAIL stock (GRAL)

Blood tests for cancer screening: GRAIL between clinical studies and Cryptonomist analyses.

Stock profile

Symbol
GRAL
Listing
NASDAQ
Sector
Healthcare
Currency
USD
Analyses published
1
First analysis

Prices are not shown on this page: you will find them in each analysis, with the trading session they refer to.

Latest analysis ·

GRAIL, Inc. stock surges 34% to $107.97, but RSI hits 81 ahead of FDA call

GRAIL, Inc. stock surged 33.68% on September 21, closing at $107.97 after an intraday high of $111.50. FDA briefing documents lifted hopes for Galleri cancer test approval ahead of the September 23 Advisory Committee. The technical picture now must catch up with a fundamentally altered…

Read the analysis

About GRAIL

GRAIL is an American diagnostics company based in Menlo Park, California, and listed on the Nasdaq. It grew out of Illumina, from which it was spun off in 2024, and develops cancer screening tests based on a simple blood draw. Its main product is Galleri, a multi-cancer detection test that looks for fragments of tumor DNA in the blood and points to the organ where the signal originates. The test is offered for a fee through physicians, while the company works to generate the data and approvals that could make it a standard screening tool.

What moves the stock

Clinical studies and regulatory decisions drive the stock. Results of large validation studies, discussions with the FDA about approval, possible reimbursement by insurers and public programs, and data on how well the test detects early-stage cancers with few false positives all count. Cash burn, the need for new capital, the number of tests sold, quarterly results and competition from other early detection methods weigh as well. Because a screening test must show both sensitivity and a low false-positive rate, each new data set is read as a verdict on the whole approach.

How to read Cryptonomist’s analyses

A cancer screening test lives on large validation studies and on talks with the FDA, and each step can change the price within hours. The daily chart shows the zones where the stock caught its breath after such news; the hourly one helps in sessions of updates on insurance reimbursement, where the first reaction often sets the tone.

All analyses on GRAIL

Other stocks

Informational content, not financial advice or an invitation to invest.